パーキンソン病治療薬の世界市場（2024年～2031年）

世界のパーキンソン病治療薬市場は、2023年に55億1,000万米ドルに達し、2031年には102億3,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは8.0%で成長する見込みです。

パーキンソン病は、運動を制御する脳の一部である黒質の神経細胞の変性によって引き起こされる神経系の進行性運動障害です。これらの神経細胞が死滅したり障害を受けると、運動制御に重要な化学物質であるドーパミンを産生する能力が失われます。米国神経外科学会（2024年）によると、パーキンソン病の症状は通常、黒質のドーパミン産生細胞が80％以上失われたときに発症します。

疫学的には、米国では毎年9万人近くがパーキンソン病と診断されており、以前の推定値である年間6万人から50％増加しているとパーキンソン財団は報告しています。ほとんどのパーキンソン病患者は、黒質に残っている細胞を刺激してドーパミンを多く産生させる薬（レボドパ薬）か、産生されたアセチルコリンの一部を阻害する薬（抗コリン薬）で治療され、脳内の化学バランスを回復させて症状を緩和します。

市場力学：

促進要因と抑制要因

革新的治療薬のイントロダクション

革新的な治療薬のイントロダクションは、治療の選択肢を広げ、患者の予後を改善することで、パーキンソン病治療薬市場を大きく押し上げると予想されます。最近の医学研究の動向は、疾患に関与する様々な経路を特異的に標的とする新しい治療法の開発につながりました。

ドパミン作動薬、MAO-B阻害薬、革新的なドラッグデリバリーシステムを含む新たな先進療法は、パーキンソン病のさまざまな病期や重症度に対応するために開発されています。例えば、アッヴィは2024年10月、進行したパーキンソン病（PD）の成人患者におけるレボドパベースの24時間皮下注療法として初めて、かつ唯一、VYALEV（ホスカルビドパおよびホスレボドパ）について米国食品医薬品局（FDA）の承認を取得しました。

このような進歩に加え、製薬企業や政府機関の研究開発への投資が増加していることも、市場の成長に寄与すると期待されるパーキンソン病治療薬のイノベーションを促進しています。例えば、2022会計年度、NINDSはNIHが支援するPD研究に総額2億5,900万米ドルのうち約1億2,500万米ドルを資金提供しました。

バイオベンチャー企業と研究機関の共同研究は、新薬や治療法の発見を加速させ、その結果、新規治療候補の評価に焦点を当てた臨床試験が急増しています。このような協力的な環境は、効果的な治療法をより迅速に市場に投入するために極めて重要です。

代替治療の存在

代替治療の存在は、患者がより魅力的または効果的と感じる可能性のある非薬物療法の選択肢を患者に提供することで、パーキンソン病治療薬市場の成長を阻害する可能性が高いです。症状の緩和を求めて、ハーブサプリメント、鍼治療、ライフスタイルの変化などの補完代替療法を実践する人が増えています。

このような選択肢が普及すれば、患者は従来の薬理学的治療よりもそれらを選択するようになり、既成薬の需要が減少し、製薬会社が市場での存在感を維持する上で課題となる可能性があります。例えば、米国国立衛生研究所（NIH）が2024年に発表した研究によると、367人のPD患者のうち、36％がPD関連の症状を緩和するために自然健康食品を使用したことがあると回答しており、コーヒー、大麻、ウコンが最も人気がありました。さらに、71％のPD患者が自然健康食品についてもっと知りたいと回答しています。このように、パーキンソン病に対する代替手段の存在は、パーキンソン病治療薬市場をの成長を阻害する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
    • 代替治療法の存在
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 疾患タイプ別

• 家族性パーキンソン病
• 特発性パーキンソン病
• 誘発性パーキンソン病
• その他

第7章 薬剤クラス別

• ドーパミン作動薬
• 末梢脱炭酸酵素阻害剤
• アデノシン遮断薬
• カテコール-O-メチルトランスフェラーゼ（COMT）阻害剤
• その他

第8章 投与経路別

• 経口
• 経皮
• 静脈内

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• AbbVie Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Acadia Pharmaceuticals Inc.
• ZAMBON COMPANY S.P.A.
• Eisai Co., Ltd.
• Acorda Therapeutics, Inc.
• Teva Pharmaceutical Industries Ltd.
• Kyowa Kirin Co., Ltd.
• Novartis AG
• Boehringer Ingelheim International GmbH
• Bausch Health Companies Inc.

第14章 付録

The global Parkinson's Disease Therapeutics market reached US$ 5.51 billion in 2023 and is expected to reach US$ 10.23 billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031.

Parkinson's disease is a progressive movement disorder of the nervous system caused by the degeneration of nerve cells in the substantia nigra, a part of the brain that controls movement. As these nerve cells die or become impaired, they lose the ability to produce dopamine, an important chemical for motor control. According to the American Association of Neurological Surgeons (2024), Parkinson's symptoms typically develop when there is an 80% or greater loss of dopamine-producing cells in the substantia nigra.

Epidemiologically, the Parkinson's Foundation reports that nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year, marking a 50% increase from the previous estimate of 60,000 diagnoses annually. Most Parkinson's patients are treated with medications that either stimulate the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or inhibit some of the acetylcholine produced (anticholinergic medications), thus restoring the chemical balance in the brain to alleviate symptoms.

Market Dynamics: Drivers & Restraints

Introduction of Innovative Therapeutics

The introduction of innovative therapeutics is expected to significantly boost the Parkinson's disease therapeutics market by expanding treatment options and enhancing patient outcomes. Recent advancements in medical research have led to the development of new therapies that specifically target various pathways involved in the disease.

New advanced therapies, including dopamine agonists, MAO-B inhibitors, and innovative drug delivery systems, are being developed to address different stages and severities of Parkinson's disease. For instance, in October 2024, AbbVie received the U.S. Food and Drug Administration (FDA) approval for VYALEV (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).

In addition to these advancements, increased investment in research and development from both pharmaceutical companies and government entities is fostering innovation for Parkinson's disease therapeutics which is expected to contribute to the market growth. For instance, In fiscal year 2022, the NINDS funded approximately $125 million out of a total of $259 million in NIH-supported PD research.

Collaborative efforts between biotech firms and research institutions are accelerating the discovery of new drugs and therapies, resulting in a surge of clinical trials focused on evaluating novel treatment candidates. This collaborative environment is crucial for bringing effective therapies to market more rapidly.

Presence of alternative treatments

The presence of alternative treatments is likely to impede the growth of the Parkinson's disease therapeutics market by offering patients a range of non-pharmacological options that they may find more attractive or effective. Individuals are practicing complementary and alternative therapies, including herbal supplements, acupuncture, and lifestyle changes, in their quest for symptom relief.

As these options become more popular, patients might choose them over traditional pharmacological treatments, which could reduce the demand for established medications and pose challenges for pharmaceutical companies in maintaining their market presence. For instance, according to a study published by the National Institute of Health (NIH) in 2024, of 367 people with PD, 36% reported having used natural health products to alleviate PD-related symptoms, with coffee, cannabis, and turmeric being the most popular. Furthermore, 71% of people with PD were interested in learning more about natural health products. Thus, the presence of alternative options for Parkinson's disease could hinder the Parkinson's disease therapeutics market.

Segment Analysis

The global Parkinson's disease therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.

Drug Class:

Drug class segment is expected to dominate the global Parkinson's disease therapeutics market share

Drug class segment is expected to dominate the global Parkinson's disease therapeutics market. This is due to the rising number of approvals of the drugs, the increasing number of drug launches and the increasing demand for this treatment option is expected to hold the segment in the dominant position. Moreover, ongoing clinical trials and research initiatives are expected to yield promising new therapies, thereby expanding the drug class offerings within the market. The focus on combination therapies that leverage the strengths of multiple drug classes is also likely to drive growth, as these approaches can provide more comprehensive symptom management. For instance, in September 2024, Amneal Pharmaceuticals, Inc. launched CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson's disease. CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. CREXONT is now broadly available at U.S. pharmacies.

Collectively, these factors position the drug class segment as a leader in the Parkinson's disease therapeutics market, ensuring sustained growth and innovation in treatment options for patients.

Geographical Analysis

North America is expected to hold a significant position in the global Parkinson's disease therapeutics market share

The North American region, particularly the United States, is projected to maintain the largest market share in the Parkinson's disease therapeutics market throughout the forecast period. This dominance is primarily due to the strong presence of major pharmaceutical companies that are actively developing advanced therapeutics for Parkinson's disease. A large number of market players in the pharmaceutical industry are present in North America particularly the United States, which enhances the availability and innovation of treatment options.

The increasing demand for Parkinson's disease therapeutics is driven by a growing incidence of the disease. For instance, according to the report published by the National Institute of Neurological Disorders and Stroke in 2024, Parkinson's disease (PD) is a chronic, progressive movement disorder that affects the lives of between 500,000 and 1 million Americans.

Market players in the region are increasingly innovating new therapeutics and solutions to meet the growing requirement for solutions for Parkinson's disease. Several companies are conducting vigorous research and clinical trials to innovate advanced solutions in the region. For instance, Neuron23 Inc. unveiled details around its global --Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in people with early Parkinson's disease (PD). The NEULARK trial represents a significant advancement in precision medicine, utilizing a state-of-the-art digital biomarker and patient stratification approach to identify individuals with LRRK2-driven PD who may be most likely to respond to treatment with NEU-411.

Asia Pacific is growing at the fastest pace in the global Parkinson's Disease Therapeutics market

The Asia-Pacific is growing at the fastest pace in the global Parkinson's disease therapeutics market. Countries like India, China, and Japan significantly contribute to this trend, resulting in a larger patient base and heightened healthcare demand. This growth is further supported by substantial investments in research and development from both public and private sectors, which are fostering innovation in treatment options. This is due to the increasing number of cases linked to a rapidly aging population.

Additionally, the expiration of patents for several well-established drugs opens doors for new market entrants and generic manufacturers, allowing them to gain a foothold in this expanding market.

Competitive Landscape

The major global players in the Parkinson's Disease Therapeutics market include AbbVie Inc., Acadia Pharmaceuticals Inc., ZAMBON COMPANY S.P.A., Eisai Co., Ltd., Acorda Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd., Novartis AG, Boehringer Ingelheim International GmbH and Bausch Health Companies Inc. among others.

Key Developments

• In September 2024, AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Parkinson's Disease Therapeutics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Introduction of innovative therapeutics
  • 4.1.2. Restraints
    • 4.1.2.1. Presence of alternative treatments
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Familial Parkinson's Disease*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Idiopathic Parkinson's Disease
• 6.4. Induced Parkinsonism
• 6.5. Others

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Dopamine Agonists*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Peripheral Decarboxylase Inhibitors
• 7.4. Adenosine Blockers
• 7.5. Catechol-O-methyltransferase (COMT) Inhibitors
• 7.6. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Transdermal
• 8.4. Intravenous

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. AbbVie Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Acadia Pharmaceuticals Inc.
• 13.3. ZAMBON COMPANY S.P.A.
• 13.4. Eisai Co., Ltd.
• 13.5. Acorda Therapeutics, Inc.
• 13.6. Teva Pharmaceutical Industries Ltd.
• 13.7. Kyowa Kirin Co., Ltd.
• 13.8. Novartis AG
• 13.9. Boehringer Ingelheim International GmbH
• 13.10. Bausch Health Companies Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us